Compare Incyte Corporation (INCY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Under Armour Inc Class A — how do they compare? Incyte Corporation trades at $113.34 (market cap $22.85B), while Under Armour Inc Class A trades at $4.84 (market cap $2.07B). The key difference: Incyte Corporation is far larger — about 11× Under Armour Inc Class A's market cap, and Incyte Corporation is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Under Armour Inc Class A for 18 Days on average.
| INCY | UA | |
|---|---|---|
Market Cap | $22.85B | $2.07B |
Volume | 1,927,029 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $7.88 |
52-Week Low | $83.80 | $3.96 |
Typical Hold Time | 33 Days | 18 Days |
Enterprise Value | $18.35B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Under Armour (UA) trades at $4.81, up 2.34% with a bullish technical signal despite mixed fundamentals. The company reported declining revenues ($5.16B in 2025, $4.9B in 2026) and negative net income margins (-9.99%), though recent quarterly earnings showed beats in Q4 2025 and Q2 2026. Analyst sentiment is divided with 39.71% buy ratings, while cash flow trends show significant outflows (-$362M net in 2025).
The outlook remains challenging with revenue declines and profitability concerns, but the stock's low P/S ratio (0.41) may attract value investors. Key risks include sustained negative cash flow, competitive pressures, and execution on turnaround strategies. Near-term performance hinges on Q3 2026 earnings and guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
